CompletedPhase 3NCT02268045
Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- mAbxience Research S.L.
- Principal Investigator
- Susana Millán, PhdmAbxience Research S.L.
- Intervention
- RTXM83(biological)
- Enrollment
- 272 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2013 – 2017
Study locations (30)
- Hosp. Interzonal "R" Carrillo, Ciudadela, Bariloche, Argentina
- Clinica Radiologica del Sur, Cipolletti, Río Negro Province, Argentina
- Clinica Viedma, Viedma, Río Negro Province, Argentina
- Hospital Britanico, Buenos Aires, Argentina
- Hospital Gral. de Agudos Donación Francisco Santojanni, Buenos Aires, Argentina
- Instituto Roffo, Buenos Aires, Argentina
- Centro Oncologico Riojano Integral (CORI), Córdoba, Argentina
- Hospital Nacional de Clinicas, Córdoba, Argentina
- Hospital Privado de Cordoba, Córdoba, Argentina
- Sanatorio Allende, Córdoba, Argentina
- Ctr. Oncologico de Rosario, Rosario, Argentina
- Inst. Cardiovascular Rosario, Rosario, Argentina
- Instituto de Hematología y Medicina Clínica Dr. Rubén Dávoli, Rosario, Argentina
- Sanatorio Parque, Rosario, Argentina
- Hospital Angel Padilla, San Miguel de Tucumán, Argentina
- +15 more locations on ClinicalTrials.gov
Collaborators
Pisa® Farmacéutica · Laboratorios de Productos Éticos C.E.I.S.A. · Laboratorio Elea Phoenix S.A. · Tecnoquimicas S.A · Innogene Kalbiotech Pte. Ltd · Libbs Farmacêutica LTDA · Key Oncologics (Pty) Ltd · Nanolek LLC · Actoverco
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02268045 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.